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Objective: To establish whether polymerase chain reaction (PCR) for cytomegalovirus deoxyribonucleic acid (DNA) can 
provide clinical information for the management of the infection. 
Methods: Leukocytes in 30 heart transplant recipients were monitored by pp65 antigen testing and PCR for 82 to 365 
days after transplantation. 
Results: Of the 30 patients, 26 developed cytomegalovirus infection, nine of whom were symptomatic. Altogether, 300 
leukocyte samples were examined. The concordance between PCR and pp65 antigen test was 82.6%. In symptomatic 
patients after surgery, PCR detected cytomegalovirus infection after 38 f 16 days and the pp65 antigen test, after 48 L 
15 days. Symptomatic infection correlated with a higher number of pp65-positive leukocytes than did asymptomatic 
infection: 310 f 356 vs 24 f 35 ( p i  0.005)/200,000 examined, respectively. Clearance of virus was observed by PCR after 
125 L 73 days (range 29 to 225) in symptomatic, and after 82 70 days (range 16 to 301) in asymptomatic, cases of 
infection. 
Conclusions: The positive predictive value of PCR for symptomatic infection was 34.6%. Our findings correlate with 
previous reports and show that the qualitative detection of cytomegalovirus DNA is not associated with overt disease 
whereas quantitation of pp65-positive leukocytes closely correlate with symptom onset. Insofar as the results are not 
quantitative, PCR is not a marker of clinically apparent infection. Careful monitoring of cytomegalovirus infection based 
on quantitative pp65 antigen assay can fulfill a l l  clinical needs for early diagnosis and proper management of the 
infection 
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Human cytomegalovirus (HCMV) infection continues 
to be a niajor cause of morbidity and mortality in 
heart transplant patients [ 1-81, Proper management of 
the infection with antiHCMV therapies, such as 
ganciclovir and foscarnet 19-11], depends on early 
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diagnosis. Procedures for prompt diagnosis as well 
as careful monitoring of viral infection have been 
developed, including direct detection of HCMV lower 
matrix phosphoprotein (pp65 antigen) [I21 in poly- 
niorphonuclear leukocytes (PMNLs), the major 
HCMV carriers in peripheral white blood cells during 
acute infection [13,14], and polymerase chain reaction 
(PCR) [IS] for HCMV deoxyribonucleic acid (DNA) 
detection in blood and tissue samples 116-291. The 
pp65 antigen test has been shown to correlate well with 
active infection and clinical disease in transplant patients 
[20-221. Moreover, change in the antigenic load, as 
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measured by the variation in pp65-positive PMNLs 
(antigenemia), also correlates with the progression of 
clinical symptoms [20,23,24]. Although PCR has 
proved to be a powerful method in diagnostic virology 
due to its high sensitivity, the clinical relevance of 
qualitative PCR results in HCMV DNA detection 
appears to be limited by a low predictive value for 
HCMV disease [20,25-271. 
The present study was designed to contribute to 
the ongoing analysis of the role of qualitative PCR 
results for HCMV DNA detection in PMNLs in heart 
transplant patients. HCMV DNA results by PCR were 
compared with quantitative detection of HCMV pp65 
in the PMNLs of 30 heart transplant recipients during 
the first year after transplantation, with emphasis on 
early identification of ongoing HCMV infection, its 
correlation with the development of clinical disease and 
monitoring of antiviral treatment. 
MATERIAL AND METHODS 
Patients 
The study involved 30 patients who had undergone 
orthotopic heart transplantation (HT) and did not 
require treatment for acute rejection between January 
1993 and July 1994 in the Cardiac Surgery Department 
at the University of Turin, Italy. All patients were 
administered a triple immunosuppressive regimen of 
prednisone, cyclosporine and azathioprine. Rabbit 
antithymocyte globulin was used for the first 10 days 
after heart transplantation. 
Human cytomegalovirus monitoring 
Virological monitoring of HCMV infection proceeded 
as follows: heparinized blood samples for pp65 antigen 
test and DNA detection were collected weekly during 
the first month after HT and then every 15 days until 
the third month. From the third to the twelfth month, 
blood was examined monthly. During the acute phase 
of HCMV infection, blood was tested twice a week. 
Meanwhile, serum samples were collected for HCMV 
serology. 
PMNL sample preparation 
PMNLs were separated by sedimentation of heparin- 
ized blood samples (3 to 7 mL) in a 6% dextran solution 
(5 vol blood/l vol dextran). Leukocytes were centri- 
fuged at 2500 rpm for I0 min at room temperature and 
the resulting pellet washed in 0.8% ammonium 
chloride (NH4C1) for 1 to 2 min to avoid blood 
contamination. PMNLs were then centrifuged and 
resuspended in 1 mL of buffered saline solution (PBS) 
at pH 7.4. Aliquots of 200,000 PMNLs were used for 
the pp65 antigen test and for DNA detection by PCR. 
pp65 antigen test (antigenemia) 
Aliquots of 200,000 PMNLs were prepared for glass 
slides using a cytocentrifuge (Cytospin 2, Shandon 
Southern Products, Astmoor, UK). PMNLs were fixed 
in 5% formaldehyde-PBS for 10 min, and air-dried 
and stained with a pool of monoclonal antibodies to 
HCMV pp65 antigen (C10-Cll; Biotest, Dreieich, 
Germany) for 45 min. After the first incubation, the 
slides were washed twice in PBS supplemented with 
1% fetal calf serum, then stained with a fluorescein- 
conjugated F(ab')2 fragment of rabbit antimouse 
immunoglobulins (Dako, Denmark). Slides were rinsed 
twice in PBS, then mounted and examined.under a 
fluorescent microscope. HCMV pp65-positive PMNLs 
were counted and referred to 200,000 examined cells. 
Different levels of antigenemia (antigenic load) were 
defined as low, moderate and high when the number 
of pp65-positive PMNLs was < 5, 5 to SO and 
> 50/200,000 examined cells, respectively [20]. 
Polymerase chain reaction for HCMV DNA 
Primers chosen for amplification by PCR were located 
within the translated region of the viral genome 
(EI1) coding for the major immediate early antigen 
(sequences 5' to 3': upstream primer AGA CCT TCA 
TGC AGA TCT CC; downstream primer GGT 
GCT CAT GCA CAT TGA TC) [28,29]. A 262 base- 
pair sequence of HCMV DNA was amplified. Aliquots 
of 1 x lo6 PMNLs were incubated in lysis buffer 
110 mM tris(hydroxymethy1)aminomethane (TR1S)- 
hydrochloric acid (HCl), SO mM potassium chloride 
(KCl), 2.5 mM magnesium chloride (MgC12), 
0.1 nig/mL gelatine, 0.45% nonidet P40 (NP40), 
0.45% polysorbate (Tween) 201 with 0.15 pg/pL 
proteinase K (International Biotechnologies, New 
Haven, CT) for 3 h at  37°C. Aliquots of 200,000 lysed 
PMNLs were subjected to DNA amplification in 
100 pL PCR reaction buffer containing 50 mmol/L 
KCI, 10 mmol/L TRIS-HCl (pH 8.3), 1.5 mmol/L 
MgC12, 20 nmol of deoxynucleoside triphosphates 
(dNTPs), 50 pmol of each primer and 2 units of 
AmpliTaq (Perkin-Elmer Cetus, Norwalk, CT). 
The PCR reaction was performed in an automated 
thermal cycler (DNA Thermal Cycler, Perkin-Elmer 
Cetus) for 40 cycles (denaturation: 94 "C for 40 sec; 
annealing: 55°C for 1 min; extension: 72 "C for 3 min 
plus 5 sec autoextension every cycle). Fifteen micro- 
litres of each amplified product were analyzed by 
electrophoresis on a 2%) agarose gel, stained with 
ethidiuni bromide and photographed. Each amplified 
sample (20 pL) was subjected to hybridization with an 
oligonucleotide probe within the amplified region of 
HCMV DNA by DNA enzyme immunoassay (Sorin 
Saluggia, Italy) [30]. 
G h i s e t t i :  P C R  v s  p p 6 5  a n t i g e n  t e s t  f o r  C M V  i n  c a r d i a c  p a t i e n t s  1 9 7  
The sensitivity of the protocol used in this study 
was determined from experiments on HCMV-infected 
fibroblasts with AD 169 and Towrie strains. The 
sensitivity was 1 infected cell in 4 x lo5 uninfected cells. 
Primer specificity was established with other related 
human herpesviruses (Epstein-Barr virus, herpes 
simplex virus types 1 and 2, varicella-zoster virus). 
To prevent carry-over of amplified DNA 
sequences and false-positive reactions, samples were 
prepared under a biosafety hood in a room physically 
isolated from that in which the P C R  was performed. 
Separate sets of supplies and positive pipetting devices 
were dedicated to saniple preparation and to assess 
reactions. All other recommended precautions for 
PCK were followed [31]. HCMV-infected huinan 
embryonic lung fibroblast cells were used as positive 
controls. Negative controls (non-infected human 
embryonic lung fibroblact cells) and a reagent mixture 
free from DNA template, considered ‘0’ DNA control, 
were used in each run. As a performance control for 
the PCK procedure, B-globin gene was routinely anipli- 
tied according to a previously described method 1311. 
HCMV serology 
Antibodies to HCMV were determined in all recipients 
before H T  and in the serum sample of every donor 
at  the time of transplantation and during the follow- 
up. HCMV-specific irriniunoglobulin G (IgG) was 
detected with enzyme-linked iiiiniunofluorescent assay 
(ELFA: VIDAS, bioMkrieux, Marcy I’Etoile, France). 
HCMV-specific IgM was determined by a u-capture 
erizy~iie-linked iriiniunosorbent assay (ELISA; Sorin, 
Saluggia, Italy), using a peroxidase-labelled HCMV 
antigen froni A D  169 strain. 
Diagnosis and treatment of HCMV infection 
Diagnostc of HCMV infection was determined by a 
positive pp65 antigen test and/or 1’CK for HCMV 
D N A  in PMNLj Iliagnocic of HCMV primary 
infection was based on virus-specific IgG sero- 
conversion from negative to positive in a seronegative 
recipient before HT. In seropositive patients before HT, 
infection was recorded as recurrent, Infected patients 
were treated with 9-(1,3-diliydroxy-2-propoxyniethyl) 
guanine (DHPG or ganciclovir) a t  the dosage of 10 
rng/kg/day intravenously for 3 3 to 21 days only when 
the infection became symptomatic (disease), when 
fever occurred in conibination with any of the follow- 
ing signs: leukopenia, thronibocytopenia, liver enzyme 
rise and gastroenteric signs. In our series, nine patients 
experienced HCMV systemic syiiiptoniatic infection. 
The most coninion clinical symptom was fever 
associated with leukopenia and/or thrombocytopenia. 
Two patients had HCMV hepatitis and one had 
gastroenteric disease. For statistical analysis, Student’s t 
test was used. 
Follow-up of heart transplant patients 
The study covered 82 to 365 days of follow-up after 
H T  (mean 230 days). Twenty-six of the 30 transplant 
patients developed HCMV infection: nine had syinpto- 
iiiatic disease Ifour primary in seronegative recipients 
(I<-) with seropositive donor (I~)+), and five recurrent 
infections in seropositive recipients (l<+)], and all were 
treated with ganciclovir. The most coni~iio~i clinic‘il 
symptom was fever associated with leukopenia and/or 
thrombocytopenia. Two primary infectioric undenvent 
two ganciclovir treatinelits due to a return of the 
infection. All patients with symptomatic infcction 
recovered with no complications. Seventeen asynipto- 
tnatic HCMV-infected patients were not treated. Tlirec 
seropositive recipients and one seronegative recipient 
with a seropositive donor had not developed H(:MV 
infection at follow-ups of 188, 179, 94 arid 365 days, 
respectively, after HT. 
Table 1 Antigenic load deterinined by pp65 antigen test compared with human cytomegalovirus (HCMV) DNA detection 
by polymerase chain reaction (PCR) in polymorphonuclear leukocytes (I’MNLs) in 26 heart transplmt patients with H<:MV 
infection 
HCMV DNA pphi Antigenic I o d :  pp65+ HCMV DNA pp65 
dppedrallcc appearance I’MNLs evaluated persistence penijtcnce 
(days after HT) (days after HT) on 200,000 cells (days after HT) (d.iyr ‘iftter HT) 
_______ 
HCMV disease 
(pi = 9) (range) 
38 f 16 48 ? 15 310 f 356** 12.5 ? 73* 65 f .50* 
(1 2 to 63) (29 to 79) (1 to 1000) (29 to 225) (18 to 172) 
HCMV asymptomatic 38 -t 41 40 ? 40 24 -t 35** 82 t 70 19 -t 32 
(n  = 17) (range) (8 to 161) (8 to 161) (1 tO 125) (16 to 301) (15 to 117) 
**I, < 0.005 (Student’s t test); * p  < 0.05 (Student’s f test). 
H T  = heart tranrplmtation. 
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Of  300 PMNL samples (5 to 22 blood samples 
for each patient, mean lo), P C R  was able to detect 
HCMV DNA in 169 (56.3%) samples, of which 117 
were also pp65 antigen test-positive (69.3%); 52 were 
pp65-negative, corresponding to early and advanced 
stages of HCMV infection after ganciclovir treatment 
in symptomatic patients. Antigenemia and P C R  gave 
negative concordant results in 131 PMNLs. The overall 
concordance between PCK and antigeneniia was 
82.6% (248 samples). 
HCMV symptomatic infection or HCMV disease 
PCR detected HCMV DNA in PMNLs 38 rfr 16 days 
after HT (range 12 to 63) and the pp65 antigen test 
became positive 48 k 15 days (range 29 to 79) after HT 
(Table 1). P C R  detected HCMV DNA 18 days (mean) 
before antigeneniia in four patients whereas, in five 
patients, the two tests proved simultaneously positive. 
Clinical symptonis appeared 55 & 15 (range 40 to 82) 
days after HT. In two patients, both P C R  and pp65 
antigen test became positive at  the onset of symptoms. 
In the other seven transplant patients, P C R  was positive 
23 days (mean) before the onset of symptoms whereas 
the pp65 antigen test showed positive at the onset of 
fever and leukopenia in one patient and, in the other 
six, 12 days (mean) before symptoms. 
In HCMV disease, the mean number of pp65- 
positive PMNLs/200,000 during an ongoing infection 
was 310 rfr 356 (range 1 to 1000). This antigenic load 
was significantly different from that in asyniptomatic 
infection (24 k 35 pp65-positive PMNLs/200,000; p < 
0.005). A statistically significant difference was also 
observed in pp65 levels at the onset of syniptoms 
between primary and reactivated infections: 542 k 395 
pp65-positive cells in primary (four patients, six 
O L ’  
Not delectable c 5 5 5 0  5&100 ,100 
pp 65 positive PMNLs l200,OOO examined cells 
Figure 1 Comparison between pp65 antigen levels at the 
time of symptom onset in patients with symptomatic 
HCMV infection and the maximum levels of pp65 
antigenemia in asymptomatic patients. 
episodes) infections and 122 rfr 157 in recurrent 
infections (five patients, five episodes; p = 0.05). In 
two of nine patients, mild fever and leukopenia were 
observed when the number of pp65-positive PMNLs 
ranged from 20 to 50 PMNLs/200,000. In four 
patients, the onset of fever and leukopenia correlated 
with an antigenic load of 50 to 100 positive PMNLs 
whereas severe clinical symptoms (hepatitis and 
gastroenteric disease) appeared when levels of 
antigeneniia exceeded 100 pp65-positive PMNLs 
(three patients; Figure 1). 
All patients underwent antiviral treatment which 
was initiated at the onset of fever and leukopenia. 
Ganciclovir therapy was discontinued when the anti- 
genic load decreased to very low levels (< 10 pp65- 
positive PMNLs/200,000) and after at least 1 week free 
ofHCMV clinical symptoms (14 to 21 days oftherapy). 
Figure 2 shows the correlation between pp65 antigen 
test and HCMV disease in two primary infections 
(patients 1 and 2). Ganciclovir therapy was started on 
days 40 and 49, respectively. During treatment, the 
antigenic load significantly decreased (< 25 pp65- 
positive PMNLs/200,000) with the disappearance of 
fever. Ganciclovir was discontinued after 21 (patient 1) 
and 14 (patient 2) days. P C R  detected HCMV DNA 
for 225 and 168 days, respectively and, in patient 1, a 
relapse of HCMV infection was observed 37 days after 
ganciclovir was discontinued. The patient was given a 
second course of therapy which resulted in a complete 
recovery. 
In all symptomatic transplant patients, PCR 
documented HCMV DNA clearance after 125 rfr 73 
(range 29 to 225) days whereas the pp65 antigen test 
became negative after 65 k 59 (range 18 to 172) days 
(p < 0.05; Table 1). In only two patients, the extended 
persistence of HCMV DNA in blood correlated 
with a relapse of HCMV infection. Both relapses were 
documented by a marked increase in antigenic load 
(720 and 1000 pp65-positive PMNLs/200,000), as 
shown in Figure 2 for patient 1. After the second course 
of ganciclovir, when the antigenic load was no longer 
detectable, HCMV DNA remained positive for 225 
and 167 days. 
IgM to HCMV was detected in six of nine (66.6%) 
patients (three primary and three recurrent infections) 
after a mean of 55 days from HT and 117 days after the 
onset of pp65 in PMNLs (data not shown). 
HCMV asymptomatic infection 
Seventeen patients experienced asymptomatic recur- 
rent infection and did not undergo antiviral treatment. 
P C R  detected HCMV DNA 38 k 41 (range 8 to 161) 
days after HT whereas antigenemia was seen after 40 k 
40 (range 8 to 161) days (Table 1). 
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Figure 1 shows the variations in antigenic load in 
asymptomatic patients. The mean number of pp65- 
positive PMNLs was 24 k 35/200,000 (range 1 to 125). 
In three PCR-positive patients, the pp65 antigen test 
was negative during monitoring. One of these pp65- 
negative patients was a D 4 R -  recipient who may have 
experienced HCMV blood transmission either by 
transfusion during surgery or by graft from a false 
seronegative donor assessed according to traditional 
serological methods. P C R  detected HCMV DNA in 
these recipients for 44, 74 and 16 days, respectively. 
During this period, the three patients were clinically 
and virologically monitored with pp65 antigen testing 
(twice a week) to detect the onset of active infection, 
which was not verified. P C R  detected HCMV infec- 
tion at  the same time as the pp65 antigen test in 10 
patients and 23 days before antigenemia in four other 
transplant patients. 
Figure 2 shows an example of the virological 
follow-up with pp65 antigen test and P C R  in two 
asymptomatic patients (patients 3 and 4). Patient 3 
Patient 1 
*O0 r--- 1 
a 
HT 4 0 4 3  5056 72 98 105 112 126 156 186 212 265 
Days from heart transplantation (HT) 
Patient 2 
40 j~ 20 HT 
43 49 54 57 61 66 211 
Days from heart transplantation (HT) 
experienced high pp65 levels (up to 125 pp65-positive 
PMNLs/200,000). This recipient was clinically and 
virologically monitored, but remained symptomless; no 
preemptive therapy was therefore administered. 
PCR detected HCMV DNA for 82 k 70 (range 
16 to 301) days whereas pp65 was detectable for 49 k 
32 (range 15 to 117) days (Tdble 1). The extended 
persistence of HCMV DNA was not associated with 
the onset of HCMV disease, and low levels of anti- 
genemia persisted for extended periods with no signs 
of disease. IgM to HCMV was positive in four of 17 
(23.5%) patients at 62 days from HT and 24 days after 
the onset of pp65 in PMNLs (data not shown). 
DISCUSSION 
The present study confirms the usefulness of a close 
follow-up of heart recipients for HCMV infection 
[20,24]. Early virological diagnosis of HCMV infection 
is mandatory and can now be achieved with the pp65 
Patient 3 
140/--- - 
1 2 0 -  
0 I 
2 1 0 0 -  
b 
8 0 -  
p 6 0 -  
8 ? 4 0 ~  
2 0 -  
v)  
n 
82 
0 -- 
HT 10 19 24 31 61 
"
a 2 6 0  
40 
- 
f 20 
Days from heart transplantation (HT) 
1 1 0  
Patient 4 
_____ 
PCR+ 
1r--- 1 
-~ L.- .- 
HT 28 31 36 43 51 71 
Days from heart transplantation (HT) 
Figure 2 Virological monitoring by pp65 antigen test and PCR for HCMV DNA in two syrnptonlatic HCMV-infected 
patients who underwent ganciclovir treatment (patients 1 and 2) and in two asymptomatic HCMV-infected patients (patients 
3 and 4). 
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antigen test, allowing the timely detection of HCMV 
disease developing from HCMV infection and thereby 
permitting prompt antiviral therapy. 
A wide range of individual responses to HCMV 
infection is seen. One critical factor is HCMV cross- 
matching between donor and recipient [2,7]. In 
the present study, four of five HCMV mismatched 
(D+/R-) patients developed HCMV disease whereas 
only five of 24 R+ (21%) recipients developed HCMV 
disease and underwent therapy. A prompt individual 
recovery of the immune system may be sufficient to 
control and resolve HCMV infection without antiviral 
therapy [8,20], as HCMV infection may be completely 
asymptomatic in some patients. 
The evolution of HCMV infection into disease, as 
seen in our study patients, correlated to pp65-positive 
PMNLs as demonstrated by a statistically significantly 
greater and different antigenic load in patients with 
HCMV disease compared with those with asympto- 
matic infection, as previously reported 120,21,23,24], 
In our experience of heart transplant patients, the 
evaluation of the antigenic load, as expressed by the 
absolute number of pp65-positive PMNLs, needs to be 
associated with the clinical status of the patient, which 
is the rationale for guided antiviral treatment. Indeed, 
although high antigenic levels (> 100 pp65-positive 
cells/200,000) are mostly associated with clinical 
disease, we found that mild symptoms such as fever and 
leukopenia could be present even when the antigenic 
load was < 100 pp65-positive PMNLs/200,000 (six of 
nine patients). O n  the other hand, moderate-to-high 
levels of antigeneniia may persist for extended periods 
[33] without symptoms. In these cases, the antigenic 
load per se cannot be sufficient to establish the clinical 
relevance of HCMVinfection, and strict clinical 
monitoring of the patient is required for the detection 
of any variation in clinical status. 
The P C R  results suggest that the procedure can 
lead, in most but not all cases, to early detection of viral 
DNA in PMNLs when the pp65 antigen test is still 
negative [16,20]. We found no correlation between the 
onset of clinical symptoms and the presence of HCMV 
DNA. The positive predictive value of HCMV DNA 
by PCK for development of HCMV disease was, in 
fact, low at 34.6%. 
According to other PCR analyses for HCMV 
infection, the results of the present study confirm that 
quantitation of pp65 antigen provides precise infor- 
mation for the clinician, especially regarding the 
efficacy of antiviral therapy [20,24,25-271. The antiviral 
treatment influences HCMV antigen expression as a 
result of less viremia whereas, because of its high 
sensitivity, PCK is able to detect small amounts of 
DNA even when the infection is latent. O n  the other 
hand, sequential negative P C R  blood samples provide 
a strong indication of the absence of HCMV infection. 
Qualitative P C R  as performed in the present study 
provided no indications concerning the viral loads that 
might be useful in the treatment and monitoring of 
HCMV infection. 
O n  the other hand, quantitative P C R  for HCMV 
DNA by coamplification of the target DNA and the 
same modified sequence as internal standard is, at 
present, such a highly complex technique as to be 
unsuitable for diagnostic and clinical purposes [34]. 
Recent reports on two new techniques, the quanti- 
tative branched-DNA amplification assay and the 
hybridization antibody-capture assay for HCMV DNA 
detection in PMNLs and other biological samples, 
suggest that these new procedures may be reliable in 
monitoring the efficacy of antiHCMV therapies and be 
suitable for the identification of patients developing 
resistance 135-381. New approaches to P C R  techniques 
are required for full comprehension of HCMV 
infection. Reverse transcription P C R  for HCMV 
messenger ribonucleic acid (mRNA) has been pro- 
posed as a highly sensitive technique for an improved 
understanding of viral replication and for the identifi- 
cation of subjects at higher risk of developing overt 
disease [39]. 
The persistence of HCMV DNA by P C R  in 
PMNLs in symptomatic and asymptomatic H T  patients 
is in agreement with previously published reports 
120,331. In some cases, the presence of HCMV DNA 
in blood may suggest that viral infection is not com- 
pletely eradicated and that a risk of viral replication 
resumption may be present. Again, only quantification 
of pp65 antigen in PMNLs correlates with overt clinical 
hsease as the extended persistence of HCMV DNA 
can be observed in syniptomless patients. 
In our experience, careful monitoring of HCMV 
infection based on the pp65 antigen test associated with 
a strict clinical evaluation of each patient can satisfy the 
clinical need for early and prompt diagnosis and 
management of HCMV infection in heart transplant 
patients. 
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